Drug intelligence / Profile preview

Huoxue Tongjiang

Development stage: Unknown
Lead developer: Tianshili Pharmaceutical Group
Administration: Oral

Overview

Huoxue Tongjiang is a patented Traditional Chinese Medicine (TCM) formula composed of multiple herbal ingredients. It is being investigated for the treatment of non-erosive reflux disease (NERD), reflux esophagitis, and Barrett's esophagus, particularly in patients presenting with Qi stagnation-blood stasis syndrome. The drug is administered orally in granule form and has demonstrated anti-inflammatory effects and the ability to promote esophageal motility.

Other names: Huoxue Tongjiang granulesHuoxue Tongjiang Formula GranulesHuoxue Tongjiang DecoctionHuoxue Tongjiang Prescription

Targets

HIF1A (Hypoxia-inducible factor 1-alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TP53 (Cellular Tumor Antigen p53 R175H)IL10 (Interleukin-10)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on Huoxue Tongjiang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huoxue Tongjiang.

Explore the full profile